Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy Journal Article
| Authors: | Ronnen, E. A.; Kondagunta, G. V.; Bacik, J.; Marion, S.; Bajorin, D. F.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J. |
| Article Title: | Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy |
| Abstract: | Purpose: To define the incidence, clinical features, and outcome to salvage chemotherapy in patients with late-relapse germ cell tumor (GCT) after a complete response to first-line chemotherapy. Patients and Methods: Two patient populations were examined. First, retrospective analysis of 246 patients treated on a clinical trial with salvage chemotherapy was performed; 29 patients with late-relapse GCT were identified and evaluated for treatment outcome and survival. Salvage regimens included paclitaxel, ifosfamide, and cisplatin, single agents, or a high-dose chemotherapy program. Second, the incidence of late relapse was assessed by retrospective analysis of 551 patients after a complete response (CR) to first-line chemotherapy. Results: Twenty-nine patients received salvage chemotherapy on a clinical trial for late relapse GCT. The median survival was 23.9 months. At a median follow-up of 50.6 months, there were nine survivors. The chemotherapy regimens varied, but the only CRs were observed in patients treated with paclitaxel, ifosfamide, and cisplatin. Seven (50%) of 14 patients treated with paclitaxel, ifosfamide, and cisplatin achieved a continuous CR. Among the second population of 551 patients who had previously achieved a CR to a first-line chemotherapy trial, 17 were identified as having a late relapse (3%). The median time to relapse for these 17 patients was 7.8 years. Conclusion: Late-relapse GCT is uncommon and is associated with a poor prognosis resulting from a high degree of resistance to chemotherapy. Chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by surgery may be effective in patients with late-relapse GCT who are not considered candidates for primary surgery. © 2005 by American Society of Clinical Oncology. |
| Keywords: | survival; adult; cancer survival; clinical article; controlled study; treatment outcome; treatment response; survival analysis; retrospective studies; clinical feature; clinical trial; salvage therapy; cisplatin; cancer combination chemotherapy; bone metastasis; paclitaxel; drug megadose; antineoplastic agent; cancer incidence; lymph node dissection; carboplatin; controlled clinical trial; neoplasm recurrence, local; etoposide; antineoplastic combined chemotherapy protocols; incidence; cyclophosphamide; pathology; retrospective study; ifosfamide; liver metastasis; lung metastasis; tumor recurrence; brain metastasis; testis tumor; testicular neoplasms; cancer relapse; orchiectomy; mesna; germ cell tumor; retroperitoneal cancer; mediastinum metastasis; germinoma |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 23 |
| Issue: | 28 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2005-10-01 |
| Start Page: | 6999 |
| End Page: | 7004 |
| Language: | English |
| DOI: | 10.1200/jco.2005.21.956 |
| PUBMED: | 16192587 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 37" - "Export Date: 24 October 2012" - "CODEN: JCOND" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work